Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 31, 2024
Discovery & Translation
Science Spotlight: Macrophage-fibroblast cross-talk in heart failure
BioCentury’s roundup of translational innovations also includes synthetic gene regulators, three longevity genes and more
BioCentury | Oct 7, 2024
Distillery Therapeutics
Inhibiting trained immunity for post-stroke heart failure
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Dec 23, 2023
Discovery & Translation
Taking next-gen mAbs to new heights will lead modality innovation
Execs and investors weigh in on which technologies will yield the biggest gains in innovation in the near term and beyond: BioCentury survey
BioCentury | Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Aug 4, 2022
Deals
Amgen sees Tavneos as growth opportunity with $4B ChemoCentryx buyout
With patent expirations ahead, deal gives Amgen immunology asset approved for vasculitis indication, with potential for label expansions
BioCentury | Apr 29, 2022
Discovery & Translation
Neoantigen-reactive T cell signatures; plus CAR T cell therapy improvements and more
BioCentury’s roundup of translational news
BioCentury | Jan 7, 2022
Deals
Novartis adds regenerative liver disease program to pipeline via Alnylam deal
First Alnylam deal announced since Yvonne Greenstreet took over as CEO
BioCentury | Sep 25, 2021
Translation in Brief
Verve’s durable PCSK9 base editor; plus Novartis, PureTech and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 120